| Literature DB >> 30275569 |
Elena J Orlando1, Xia Han2, Catherine Tribouley2, Patricia A Wood2, Rebecca J Leary3, Markus Riester3, John E Levine4, Muna Qayed5, Stephan A Grupp6, Michael Boyer7, Barbara De Moerloose8, Eneida R Nemecek9, Henrique Bittencourt10, Hidefumi Hiramatsu11, Jochen Buechner12, Stella M Davies13, Michael R Verneris14, Kevin Nguyen15, Jennifer L Brogdon3, Hans Bitter3, Michael Morrissey3, Piotr Pierog2, Serafino Pantano16, Jeffrey A Engelman3, Wendy Winckler3.
Abstract
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19- relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30275569 DOI： 10.1038/s41591-018-0146-z
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440